• Emerging Cell Therapies for Blood Cancers with Arcellx CMO, Chris Heery, MD

  • Sep 5 2024
  • Length: 30 mins
  • Podcast

Emerging Cell Therapies for Blood Cancers with Arcellx CMO, Chris Heery, MD

Listen for free

View show details

  • Summary

  • In this podcast episode, we sit down with Christopher Heery, the Chief Medical Officer at Arcellx to learn about the company's pipeline and lead cell therapy, anitocabtagene autoleucel, or anito-cel, that is in development for multiple myeloma. Multiple myeloma, like lymphoma and leukemia are types of cancer that start in your blood cells.
    Show more Show less
Show more Show less

What listeners say about Emerging Cell Therapies for Blood Cancers with Arcellx CMO, Chris Heery, MD

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available